Showing 5001-5010 of 5909 results for "".
- Aura Biosciences Doses First Patient in Phase 2 Study Evaluating Suprachoroidal Administration of AU-011 in Patients with Choroidal Melanomahttps://modernod.com/news/aura-biosciences-doses-first-patient-in-phase-2-study-evaluating-suprachoroidal-administration-of-au-011-in-patients-with-choroidal-melanoma/2478272/Aura Biosciences announced the dosing of the first patient in a phase 2 study evaluating the safety and efficacy of suprachoroidal (SC) administration of AU-011, the company’s lead product candidate, as a potential first-line treatment for patients with primary choroidal melanoma. “I am ho
- Study to Investigate If Those With Diabetic Eye Disease Are At Greater Risk of COVID-19 Complicationshttps://modernod.com/news/study-to-investigate-if-those-with-diabetic-eye-disease-are-at-greater-risk-of-covid-19-complications/2478267/Fight for Sight is partnering with Diabetes UK to investigate if people with diabetic retinopathy are at greater risk of developing complications from COVID-19, in a study that hopes to save lives. This research, which will be carried out at the University of Edinburgh, will investigate wh
- The Vision Council Launches New Brand Identity and Member-Focused Websitehttps://modernod.com/news/the-vision-council-launches-new-brand-identity-and-member-focused-website/2478260/The Vision Council announced the launch of a new brand identity, including a reimagined logo and a new website designed to better serve and accommodate the needs of members and the vision care community at large. The rebrand and website launch represent the initial phase of the plan The Vision Co
- Regenxbio Announces Dosing of First Patient in Phase 2 AAVIATE Trial of RGX-314 for the Treatment of Wet AMDhttps://modernod.com/news/regenxbio-announces-dosing-of-first-patient-in-phase-2-aaviate-trial-of-rgx-314-for-the-treatment-of-wet-amd/2478257/Regenxbio announced that the first patient has been dosed in the AAVIATE trial, a phase 2 trial to evaluate the suprachoroidal delivery of RGX-314 using the SCS Microinjector for the treatment of wet age-related macular degeneration (AMD). The company expects to report interim data from the first
- Independent, Smaller Hospitals Will Need to Make Tough Choices to Survive COVID-19 Financial Crisis: Analysishttps://modernod.com/news/independent-smaller-hospitals-will-need-to-make-tough-choices-to-survive-covid-19-financial-crisis-analysis/2478252/Independent hospitals could need to make drastic decisions such as reducing service lines or workforces to survive the cash crisis caused by the COVID-19 pandemic, a new analysis finds, according to a FierceHealthcare
- Liminal BioSciences Announces Resubmission of Biologics License Application to FDA for Ryplazimhttps://modernod.com/news/liminal-biosciences-announces-resubmission-of-biologics-license-application-to-fda-for-ryplazim/2478254/Liminal BioSciences announced that the company, through its U.S. subsidiary Prometic Biotherapeutics, has filed a resubmission of the biologics license application (BLA) for Ryplazim (plasminogen) (Ryplazim) with the FDA for the treatment of congenital plasminogen deficiency (C-PLGD). “The
- Graybug Vision Appoints Robert Breuil as Chief Financial Officerhttps://modernod.com/news/graybug-vision-appoints-robert-breuil-as-chief-financial-officer/2478245/Graybug Vision announced the appointment of Robert S. Breuil as chief financial officer, effective immediately. Mr. Breuil succeeds Daniel Geffken, founder and managing director of Danforth Advisors, who led the function as ad-interim CFO. “I am excited to welcome Robert Breuil to the Gray
- CEO Expects Pfizer Will Know By October If COVID-19 Vaccine Workshttps://modernod.com/news/ceo-expects-pfizer-will-know-by-october-if-covid-19-vaccine-works/2478246/Pfizer CEO Albert Bourla said that late-stage study results could be available by the end of October for a coronavirus vaccine it is co-developing with BioNTech, adding “we should have enough [data]…to say whether the product works or not.” His remarks come in the wake of the Trump ad
- Alimera Sciences Announces Enrollment of First Patient in NEW DAY Clinical Trial to Evaluate Iluvien as Baseline Therapy for DMEhttps://modernod.com/news/alimera-sciences-announces-enrollment-of-first-patient-in-new-day-clinical-trial-to-evaluate-iluvien-as-baseline-therapy-for-dme/2478243/Alimera Sciences announces that it has enrolled the first patient in the company’s NEW DAY clinical trial, a randomized, controlled, multicenter study designed to generate prospective data for Iluvien (fluocinolone ac
- Medical Optometry America to Open First Practice Location in Southcentral Pennsylvaniahttps://modernod.com/news/medical-optometry-america-to-open-first-practice-location-in-southcentral-pennsylvania/2478237/Medical Optometry America (MOA) announced their first practice location will open in Shrewsbury, Pennsylvania in late 2020 and will be led by MOA’s Regional Clinical Director Leslie O’Dell, OD, FAAO. As the first national optometric brand focused exclusively on medical eye care, MOA is lau